UK reports of persistent sexual dysfunction after discontinuation of finasteride
Since the first report was received in November 1992, the UK’s MHRA has received 426 Yellow Card reports up until 5 April 2024 of finasteride (both 1mg and 5mg formulations) and sexual dysfunction, including reports of erectile dysfunction and decreased sex drive. In almost half of these reports, the outcome was recorded as ‘not recovered’ or ‘not resolved’.
UK reports of psychiatric dysfunction with finasteride
Since the first report was received in February 1993, the UK’s MHRA has received 281 reports of finasteride and depressed mood disorders and suicidal and self-injurious behaviours, up until 5 April 2024.
- TRADE NAMES: Pro-Cure; Propecia (Merck); Proscar (Merck); Proscar 5
- INDICATIONS: Benign prostatic hypertrophy, male-pattern baldness
- CLASS: 5-alpha reductase inhibitor, Androgen antagonist, Enzyme inhibitor
- HALF-LIFE: 5–8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Contra-indicated in women
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/21/2024
